Carboplatin

Colorectal Adenocarcinoma

AkesoSmall moleculePhase 1/2Active

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 40/ 100
Competitive Position: 73/ 100

Competitive context

66 Active assets in the Colorectal Adenocarcinoma cohort.

Asset / Sponsor	Phase	Rating
Trifluridine Centre Hospitalier Universitaire Dijon	Phase 3	BB
Regorafenib City of Hope Medical Center	Phase 2	BB
Botensilimab City of Hope Medical Center	Phase 2	BB
Balstilimab City of Hope Medical Center	Phase 2	BB
Cetuximab Bayer	Phase 2	BB

View all 50 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant

A

Indicative ·

80 / 100

non-small cell squamous lung carcinomaDormant

BBB

Indicative ·

76 / 100

primary peritoneal carcinomaDormant

BBB

Indicative ·

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.